title: Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.
abstract: The frequency of BRCA1 and BRCA2 mutations in women with breast cancer varies according to the age at diagnosis, family history of cancer, and ethnicity/country of origin. We set out to estimate the frequency of seven previously described founder mutations in BRCA1 and BRCA2 in all eligible French Canadian women diagnosed with invasive breast cancer at one Montreal hospital over a 20-month period. One hundred and ninety-two patients were eligible and 127 (66.2%) provided blood for genetic testing. We identified 4 women who carried a founder mutation (3.1%, 95% confidence interval 0.9-7.9%) in this population. Interestingly, all the mutations were in BRCA2. The mean age at diagnosis for mutation carriers was 51.2 years (range 49.1-53.5). Two of these 4 cases were lobular invasive carcinomas and 2 were ductal carcinomas, histological grade 1 or 2. Despite a small tumor size (< or =20 mm), axillary nodal involvement was present in 3 women. Estrogen receptors were strongly expressed in all cases. Two of the 4 cases reported a strong family history of breast cancer, but a family history of site-specific breast cancer was a relatively poor indicator of the presence of BRCA2 mutations. The absence of BRCA1 mutations may be a result of chance, but may also reflect different geographical origins of the most common BRCA1 mutations within the French Canadian population.
authors.affiliation: McGill University Health Centre Research Institute, McGill University, Montreal, Quebec, Canada.
authors.forename: P O
authors.initials: PO
authors.lastname: Chappuis
authors.forename: N
authors.initials: N
authors.lastname: Hamel
authors.forename: A J
authors.initials: AJ
authors.lastname: Paradis
authors.forename: J
authors.initials: J
authors.lastname: Deschênes
authors.forename: A
authors.initials: A
authors.lastname: Robidoux
authors.forename: C
authors.initials: C
authors.lastname: Potvin
authors.forename: J
authors.initials: J
authors.lastname: Cantin
authors.forename: P
authors.initials: P
authors.lastname: Tonin
authors.forename: P
authors.initials: P
authors.lastname: Ghadirian
authors.forename: W D
authors.initials: WD
authors.lastname: Foulkes
mesh_terms: D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D002170:Canada / Q000453:epidemiology; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D005260:Female; D018703:Founder Effect; D005602:France; D018095:Germ-Line Mutation; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D015995:Prevalence; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D019313:BRCA1 Protein; D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors